Mucuna pruriens (velvet bean)

Plant source of L-DOPA. Used in Ayurveda for Parkinson disease; in the West – biohacking supplement

ATC code: A11JA-MUCUNA (Mucuna pruriens)

Brand names – supplements

Now Dopa Mucuna, Himalaya Mucuna, Solaray Mucuna Pruriens, Gaia Herbs Mucuna

Supplements are not tested in clinical trials and are not registered as medications.

Mechanism of action

Mucuna seeds contain natural L-DOPA (levodopa) at 4-7%, making mucuna the only significant plant source of this substance. L-DOPA crosses the blood-brain barrier and is decarboxylated to dopamine in dopaminergic neurones (same mechanism as pharmacological levodopa-carbidopa). Besides L-DOPA, mucuna contains alkaloids (mucunine, prurine) and serotonin analogues. Key difference from pharmacological levodopa: mucuna lacks a peripheral decarboxylase inhibitor (carbidopa, benserazide), so a significant L-DOPA fraction is converted to dopamine peripherally, causing nausea, vomiting and cardiovascular effects.

Indications

Parkinson's disease

Adjunct

Mucuna is the only plant preparation containing significant L-DOPA (4-7% in seeds). Katzenschlager 2004 RCT (J Neurol Neurosurg Psychiatry) in 8 Parkinson patients showed mucuna (30 g seed powder) had pharmacokinetic profile comparable to levodopa/carbidopa 200/50 mg, with faster onset and longer duration. MDS 2018 evidence-based medicine review does not include mucuna in proven-efficacy preparations for Parkinson motor symptoms; standard levodopa/carbidopa or levodopa/benserazide remains the only first-line under expert neurology supervision. AEMPS and do not register mucuna as a medicine. Self-administration of mucuna in Parkinson is unsafe: unpredictable L-DOPA concentration across seed batches, absence of peripheral decarboxylase inhibitor (significant peripheral effects), drug interaction risk with MAO-I, antipsychotics and antihypertensives.

Sources

J Neurol Neurosurg Psychiatry: Mucuna pruriens in Parkinson disease: a double-blind clinical and pharmacological study (2004)

Marketing claims without evidence base

The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.

Erectile dysfunction

Not recommended

Mucuna is sold in the biohacking segment as «natural Viagra» on the dopaminergic libido modulation hypothesis. No evidence base in erectile dysfunction: no significant RCTs with IIEF or sexual function scale endpoints. AUA 2018 lists PDE-5 inhibitors (sildenafil, tadalafil, vardenafil, avanafil) first-line for ED; mucuna is not mentioned. If mucuna was recommended for ED instead of workup (testosterone, , lipid panel, TSH) and standard therapy, consider seeking a second opinion from a urologist.

Sources

AUA: Erectile Dysfunction: AUA Guideline (2018)

Low testosterone in men (supplement marketing)

Not recommended

Mucuna in the biohacking segment is sold as a «natural testosterone booster» promising male fertility and sexual function. No evidence base: small Indian studies with small samples and weak methodology. Endocrine Society 2018 in confirmed hypogonadism recommends testosterone replacement therapy via injections, gel or implants; mucuna is not mentioned. If mucuna was recommended for «low testosterone» without proper workup (total + free testosterone morning, LH, FSH, prolactin, SHBG, ferritin), consider seeking a second opinion from an endocrinologist.

Sources

AUA: Erectile Dysfunction: AUA Guideline (2018)

Mild-to-moderate depression

Not recommended

Mucuna is sold in the biohacking segment as a «natural antidepressant» on the dopaminergic mood modulation hypothesis via L-DOPA. No evidence base in depression: no significant RCTs. 2022 and SEP 2014 list CBT and SSRIs first-line for mild-to-moderate depression; mucuna is not mentioned. Main risk: mucuna contains L-DOPA and interacts with MAO-I, antipsychotics and antihypertensives – self-administration is unsafe. If mucuna was recommended for depression instead of a psychiatric consultation, consider seeking a second opinion.

Sources

NICE: Depression in adults: treatment and management (NG222) (2022)

Check interaction with another drug

Opens the checker prefilled with this drug. Pick the second one from your regimen.

Open checker

Safety

Contraindications

Pregnancy and lactation
Children under 18
Bipolar disorder and psychotic states (risk of mania and psychosis induction via dopaminergic effect)
MAO-I therapy (phenelzine, moclobemide, selegiline, methylene blue) – hypertensive crisis risk
Antipsychotic therapy (antagonism)
Melanoma or suspected melanoma (L-DOPA contraindicated)
Closed-angle glaucoma
Severe cardiovascular disease, arrhythmias

Serious adverse effects

Psychosis and hallucinations (especially in the elderly)
Hypertensive crisis combined with MAO-I
Serotonin syndrome (if serotonin analogue impurities present)
Impulse control disorders (pathological gambling, hypersexuality, compulsive shopping) – known for pharmacological L-DOPA

Common adverse effects

Nausea, vomiting
Orthostatic hypotension
Palpitations, tachycardia
Insomnia
Skin itch (seed hair contact)
Dyskinesias (with long-term high doses)

PregnancyFDA N

No RCT data in pregnancy. Contains L-DOPA, theoretical risk of effect on developing fetal dopaminergic system. AEMPS does not register. Avoid in pregnancy.

Breastfeeding

No data on milk transfer. Pharmacological L-DOPA suppresses prolactin secretion; theoretical risk of reduced lactation. Lactating women should avoid.

Calculate RID

Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.

Frequently asked

What is Mucuna pruriens (velvet bean) used for?

Mucuna pruriens (velvet bean) is evaluated for the following indications with varying evidence strength: Parkinson's disease (evidence tier C), Erectile dysfunction (evidence tier F), Low testosterone in men (supplement marketing) (evidence tier F). See the full indication matrix with dosing and citations above on this page.

What are the side effects of Mucuna pruriens (velvet bean)?

Common side effects of Mucuna pruriens (velvet bean) (≥ 1 in 100): Nausea, vomiting, Orthostatic hypotension, Palpitations, tachycardia, Insomnia, Skin itch (seed hair contact), Dyskinesias (with long-term high doses). See the Safety section for uncommon and serious reactions.

Is Mucuna pruriens (velvet bean) safe during pregnancy?

FDA category N. No RCT data in pregnancy. Contains L-DOPA, theoretical risk of effect on developing fetal dopaminergic system. AEMPS does not register. Avoid in pregnancy.

Is Mucuna pruriens (velvet bean) compatible with breastfeeding?

No data on milk transfer. Pharmacological L-DOPA suppresses prolactin secretion; theoretical risk of reduced lactation. Lactating women should avoid.

Who should not take Mucuna pruriens (velvet bean)?

Mucuna pruriens (velvet bean) is contraindicated in: Pregnancy and lactation; Children under 18; Bipolar disorder and psychotic states (risk of mania and psychosis induction via dopaminergic effect); MAO-I therapy (phenelzine, moclobemide, selegiline, methylene blue) – hypertensive crisis risk; Antipsychotic therapy (antagonism). Full list in the Safety section.

Mechanism of action

Indications

Parkinson's disease

Adjunct

Sources

J Neurol Neurosurg Psychiatry: Mucuna pruriens in Parkinson disease: a double-blind clinical and pharmacological study (2004)

Safety

Contraindications

Pregnancy and lactation
Children under 18
Bipolar disorder and psychotic states (risk of mania and psychosis induction via dopaminergic effect)
MAO-I therapy (phenelzine, moclobemide, selegiline, methylene blue) – hypertensive crisis risk
Antipsychotic therapy (antagonism)
Melanoma or suspected melanoma (L-DOPA contraindicated)
Closed-angle glaucoma
Severe cardiovascular disease, arrhythmias

Serious adverse effects

Psychosis and hallucinations (especially in the elderly)
Hypertensive crisis combined with MAO-I
Serotonin syndrome (if serotonin analogue impurities present)
Impulse control disorders (pathological gambling, hypersexuality, compulsive shopping) – known for pharmacological L-DOPA

Common adverse effects

Nausea, vomiting
Orthostatic hypotension
Palpitations, tachycardia
Insomnia
Skin itch (seed hair contact)
Dyskinesias (with long-term high doses)

PregnancyFDA N

No RCT data in pregnancy. Contains L-DOPA, theoretical risk of effect on developing fetal dopaminergic system. AEMPS does not register. Avoid in pregnancy.

Breastfeeding

No data on milk transfer. Pharmacological L-DOPA suppresses prolactin secretion; theoretical risk of reduced lactation. Lactating women should avoid.

Calculate RID

Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.

Frequently asked

What is Mucuna pruriens (velvet bean) used for?

What are the side effects of Mucuna pruriens (velvet bean)?

Is Mucuna pruriens (velvet bean) safe during pregnancy?

FDA category N. No RCT data in pregnancy. Contains L-DOPA, theoretical risk of effect on developing fetal dopaminergic system. AEMPS does not register. Avoid in pregnancy.

Is Mucuna pruriens (velvet bean) compatible with breastfeeding?

No data on milk transfer. Pharmacological L-DOPA suppresses prolactin secretion; theoretical risk of reduced lactation. Lactating women should avoid.

Who should not take Mucuna pruriens (velvet bean)?